Anti-tumor responses were lost following CD8+, but not CD4+, T-cell depletion and enhanced by PD1 blockade, confirming that tumor cell-derived Type I IFNs lead to a tumoricidal adaptive immune response (Fig. 5h, i). The gene discussed is CD4; the disease is neoplasm.